These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Search MEDLINE/PubMed

  • Title: Effect of induction agent on posttransplant outcomes in deceased donor kidney transplant recipients: influence of race.
    Author: Hussain SM, Sureshkumar KK, Ko TY, Marcus RJ.
    Journal: Transplant Proc; 2013; 45(1):119-21. PubMed ID: 23283292.
    Abstract:
    BACKGROUND: The effect of induction agents on kidney transplant outcomes with respect to race is not well studied. We aimed to compare the outcomes of deceased donor kidney (DDK) transplants in African American (AA) and non-African American (non-AA) recipients who underwent induction therapy with rabbit-antithymoglobulin (rATG), alemtuzumab (ALE), or interleukin (IL)-2 receptor blocker (IL-2B) and were maintained on a calcineurin inhibitor, (CNI)/mycophenolate mofetil (MMF)-based regimen with/without steroid. METHODS: Using OPTN/UNOS database, we identified patients (≥18 years) who underwent DDK transplants from January 2000 to December 2008 and received rATG (n = 21,506), ALE (n = 3476), or IL- 2B (n = 17,869) and were maintained on a CNI/MMF-based regimen with/without steroids. Multivariate analysis was performed adjusting for steroid use and factors known to adversely impact graft outcome. RESULTS: The median follow up was 29.6 months (range, 10.7-60.1). ALE induction as compared to rATG had inferior adjusted graft (P < .001) and patient (P = .003) survivals in non-AA recipients but similar in AA recipients. In non-AA recipients, IL-2 induction as compared with rATG had similar adjusted graft but inferior patient survival (P = .04), and in AA recipients had inferior graft (P = .002) but similar patient survival. CONCLUSION: Our study shows racial differences in renal transplant outcomes with regard to induction modality.
    [Abstract] [Full Text] [Related] [New Search]